IDEAYA, I-Mab, Immunic to be added to NASDAQ Biotechnology Index

 

• IDEAYA Biosciences (IDYA -1.5%), I-Mab (IMAB +2.4%) & Immunic (IMUX +3.9%) were selected for addition to the NASDAQ Biotechnology Index, effective Dec.21, 2020 before market opens.
• "Since its IPO on Nasdaq in January 2020, I-Mab has successfully executed many important business milestones and significantly elevated its capital market profile. The inclusion in the NBI, following the first annual review by Nasdaq since our IPO, further validates I-Mab's progress and potential in delivering value to shareholders. We look forward to sharing many more achievements in 2021 and beyond," I-Mab director & CFO Mr. Jielun Zhu commented.
• In comparison to the gain in the iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB) past 1-year performance, which tracks the index, IDYA, IMAB and IMUX have garnered higher returns in the same period.
• https://seekingalpha.com/news/3644196-ideaya-biosciences-i-mab-immunic-will-be-added-to-nasdaq-biotechnology-index